Recommended changes to oncology clinical trial design: Revolution or evolution?

被引：31

作者：

Ratain, Mark J. ^{[1
]}

Humphrey, Rachel W. ^{[2
]}

Gordon, Gary B. ^{[3
]}

Fyfe, Gwen ^{[4
]}

Adamson, Peter C. ^{[5
]}

Fleming, Thomas R. ^{[6
]}

Stadler, Walter M. ^{[1
]}

Berry, Donald A. ^{[7
]}

Peck, Carl C. ^{[8
]}

机构：

[1] Univ Chicago, Chicago, IL 60637 USA

[2] Bristol Myers Squibb Co, Wallingford, CT 06492 USA

[3] Abbott Labs, Abbott Pk, IL 60064 USA

[4] Genentech Inc, San Francisco, CA 94080 USA

[5] Childrens Hosp, Philadelphia, PA 19104 USA

[6] Univ Washington, Seattle, WA 98195 USA

[7] Univ Texas Houston, MD Anderson Canc Ctr, Houston, TX 77030 USA

[8] Univ Calif San Francisco, San Francisco, CA 94143 USA

来源：

EUROPEAN JOURNAL OF CANCER | 2008年 / 44卷 / 01期

关键词：

D O I：

10.1016/j.ejca.2007.09.011

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：8 / 11

页数：4

共 32 条

[1]

[Anonymous], GUID IND PREM RISK A

[2]

[Anonymous], 1999, GUID IND CLIN DEV PR

[3] Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework [J].

Atkinson, AJ ;

Colburn, WA ;

DeGruttola, VG ;

DeMets, DL ;

Downing, GJ ;

Hoth, DF ;

Oates, JA ;

Peck, CC ;

Schooley, RT ;

Spilker, BA ;

Woodcock, J ;

Zeger, SL .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (03) :89-95

[4] Design and conduct of phase II studies of targeted anticancer therapy: Recommendations from the task force on methodology for the development of innovative cancer therapies (MDICT) [J].

Booth, Christopher M. ;

Calvert, A. Hilary ;

Giaccone, Giuseppe ;

Lobbezoo, Marinus W. ;

Eisenhauer, Elizabeth A. ;

Seymour, Lesley K. .

EUROPEAN JOURNAL OF CANCER, 2008, 44 (01) :25-29

[5] Endpoints and other considerations in phase I studies of targeted anticancer therapy: Recommendations from the task force on methodology for the development of innovative Cancer Therapies (MDICT) [J].

Booth, Christopher M. ;

Calvert, A. Hilary ;

Giaccone, Giuseppe ;

Lobbezoo, Marinus W. ;

Seymour, Lesley K. ;

Eisenhauer, Elizabeth A. .

EUROPEAN JOURNAL OF CANCER, 2008, 44 (01) :19-24

[6]

*EUR MED AG, 1998, ICH TOP E 8 GEN CONS

[7]

European Medicines Agency, 2001, ICH TOP E 10 CHOIC C

[8]

European Medicines Agency, 1994, ICH TOP E 4 DOS RESP

[9]

European Medicines Agency, 1998, ICH Topic E 9 statistical principles for clinical trials

[10]

FDA, 2003, GUID IND EXP RESP RE

← 1 2 3 4 →